Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4)

Detalles Bibliográficos
Autores principales: AlEid, Ahmad, Balkhi, Areej Al, Alqutub, Adel, Abbarh, Shahem, Allehibi, Abed, Almtawa, Abdullah, Alotaibi, Nawwaf, Alghamdi, Ahmed G., AlGhamdi, Adel, Alamr, Abdulrahman, Ahmad, Shameem, Alsayari, Khalid, AlIbrahim, Bashaar, Khathlan, Abdullah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AGA Institute. Published by Elsevier Inc. 2022
Materias:
AASLD Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212490/
http://dx.doi.org/10.1016/S0016-5085(22)63449-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212490/
http://dx.doi.org/10.1016/S0016-5085(22)63449-8

Ejemplares similares